IMDX · Insight Molecular Diagnostics Inc.

This 8-K/A filing addresses an administrative correction by reclassifying the disclosure of a Specimen Collection Agreement with Quest Diagnostics from Item 1.01 (Material Definitive Agreements) to Item 8.01 (Other Events). The agreement, announced on February 20, 2026, supports specimen collection services specifically for the company's GraftAssureCore TM test, which measures donor-derived cell free DNA using a novel PCR-based platform. For investors, this amendment ensures proper categorization without altering the underlying facts of the partnership, potentially signaling that the company views the agreement as operational rather than a core material contract impacting financials or control. The move to Item 8.01 may reduce perceived immediacy but highlights a strategic collaboration with a major diagnostics player like Quest Diagnostics to facilitate commercialization of this transplant monitoring test.